What are your top takeaways from IDWeek 2025?

• The professional ID community is still strongly interested in the power of vaccines to prevent infectious diseases and improve the health of the world.
• New anti-fungal agents show promise for treating difficult mold infections
• Changing climate and increased mobility are shifting the traditional geographic “homes” of endemic environmental pathogens.

One takeaway is that many clinicians are struggling to understand when to use oral therapy for serious infections such as osteomyelitis and endocarditis. People are not happy with the drug combinations and doses that were proposed in the recent clinical trials, and are also still trying to determine how to incorporate this into daily practice. People are looking for protocols.

There was a very interesting and informative session on the pros and cons of using Multiplex PCR testing for respiratory...

• Rapid progress in the science of HIV prevention (via PrEP and vaccine development), antifungal therapies, and treatment of severe bacterial infections (like endocarditis) is generating enthusiasm tempered by serious logistical, equity, and governmental funding concerns.
• In Transplant and Oncology ID, more intense focus is being given to the management of non-SARS-CoV-2 respiratory viruses and more atypical disorders (e.g., HHV8-related diseases).